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Background: There are potential conflicts between authorities and companies to fund new premium priced drugs
especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the
prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective
treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known
antidote and dependence on renal elimination. Published studies showed dabigatran to be cost-effective but there are
budget concerns given the prevalence of AF. These concerns resulted in extensive activities pre- to post-launch to manage
its introduction.
Objective: To (i) review authority activities across countries, (ii) use the findings to develop new models to better manage
the entry of new drugs, and (iii) review the implications based on post-launch activities.
Methodology: (i) Descriptive review and appraisal of activities regarding dabigatran, (ii) development of guidance for key
stakeholder groups through an iterative process, (iii) refining guidance following post launch studies.
Results: Plethora of activities to manage dabigatran including extensive pre-launch activities, risk sharing arrangements,
prescribing restrictions and monitoring of prescribing post launch. Reimbursement has been denied in some countries
due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance
is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities.
Post-launch activities include increasing use of patient registries to monitor the safety and effectiveness of new drugs in
clinical practice.
Conclusion: Models for introducing new drugs are essential to optimize their prescribing especially where concerns.
Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.
Keywords: critical drug evaluation, dabigatran, demand-side measures, managed introduction new medicines, registries
BACKGROUND
Pharmaceutical expenditure is under increasing scrutiny, rising
by more than 50% in real terms during the past decade among
OECD countries (Godman et al., 2013). This rate will continue
unless addressed driven by well-known factors including chang-
ing demographics and the continual launch of new premium
priced products (Garattini et al., 2008; Godman et al., 2013;
Malmström et al., 2013). Continued pressure on resources is
already resulting in some countries unable to fund new premium
priced drugs (Malmström et al., 2013). The number of countries
is likely to increase if not addressed with new drugs, including
new biological drugs, being launched at US$100,000–400,000 per
patient per year or more (Kaiser, 2012; Godman et al., 2013;
Malmström et al., 2013). This is in no one’s best interest especially
if new medicines help improve patients’ health either because
they are more effective, have less side-effects, are easier to admin-
ister than current standards or a combination of these factors
(Malmström et al., 2013; Spatz and McGee, 2013).
Premium prices for new medicines are a concern among
health authorities struggling to maintain, and potentially
incompatible with, the European ideals of comprehensive and
equitable healthcare (Garattini et al., 2008; Malmström et al.,
2013). This can lead to conflicts between authorities and
pharmaceutical companies with the latter keen to re-coup
the considerable monies spent on Research and Development
through encouraging the rapid reimbursement and uptake of
new medicines. Uptake can be enhanced by companies spend-
ing up to one third of their income on marketing activities
alongside lobbying activities (Civaner, 2012; Malmström et al.,
2013).
KEY CONCEPT 1 | Concerns with new medicines
Pharmaceutical expenditure is under increasing scrutiny among health
authorities given ongoing pressures. Premium prices for new medicines
are a concern especially if there are safety concerns with new medicines
in clinical practice, which applied to new oral anticoagulants.
These conflicts between companies and authorities can be
greater when there are safety concerns with new drugs, and they
are subsequently prescribed in a wider population than studied
in randomized clinical trials. Typically Phase III clinical trials are
conducted under ideal and highly controlled conditions to seek
high internal validity to maximize the chance of demonstrating
Frontiers in Pharmacology www.frontiersin.org June 2014 | Volume 5 | Article 109 | 2
Godman et al. Dabigatran—a case history
clinical benefit (Fritz and Cleland, 2003). However, this may lead
to substantial differences from their subsequent use in clinical
practice. Typically Phase III clinical trials do not include treat-
ment preferences and/or multimodal treatment programs (Wells,
1999; Fritz and Cleland, 2003). Phase III clinical trials may also
include a placebo group as a comparator in order to isolate the
effects of a particular intervention (Fritz and Cleland, 2003).
These situations can lead to concerns with the generalizability of
the findings when new drugs are being considered as an alterna-
tive to current treatments, especially once prescribed in patients
with greater co-morbidities than those enrolled into Phase III
clinical trials. They have also led to product withdrawals, which is
in no one’s best interest. Examples include zimelidine, rofecoxib,
and natalizumab (Malmström et al., 2013).
New oral anticoagulants (NOACs) illustrate some of these ten-
sions as they show promise in the prevention of stroke in patients
with atrial fibrillation (AF), offering an alternative to warfarin
without the need for INR (International Normalized Ratio) mon-
itoring (Pink et al., 2011; Mannuci et al., 2012; Malmström et al.,
2013). However, there are safety concerns especially in the elderly
in addition to potential compliance problems (Mannuci et al.,
2012; Malmström et al., 2013; Marshall et al., 2013; Xu et al.,
2013).
AF is the most common clinically significant cardiac arryth-
mia with an estimated prevalence of 1–2% of the population
(Marshall et al., 2013). Current estimates suggest there are 4.5
million people in Europe with AF and 3.03 million in the US
(Marshall et al., 2013), with the prevalence of AF likely to dou-
ble in the next 50 years with ageing populations (Pink et al.,
2011; Malmström et al., 2013; Marshall et al., 2013). New drugs
are needed since patients with AF have a 5-fold increased risk
of cardioembolic stroke compared with those in sinus rhythm
(Pink et al., 2011), with a cardioembolic stroke resulting in
approximately 20% of patients dying in the acute phase and 60%
developing severe disability (Mannuci et al., 2012). In addition,
those patients with AF who survive are left more disabled by their
stroke and are more likely to have a recurrence than those with
other causes of stroke (Malmström et al., 2013).
Anticoagulant therapy with Vitamin K antagonists (VKAs) can
reduce by at least 60% the risk of stroke (Malmström et al., 2013).
However, there are concerns with warfarin due to the potential of
bleeding, the need to tailor doses to the individual with too high
a dose potentially causing serious complications and too low a
dose losing protection, and the difficulties with maintaining some
patients within International Normalized Ratios (Mannuci et al.,
2012; Malmström et al., 2013).
Dabigatran received EU marketing authorization in August
2011 (Malmström et al., 2013) for the prevention of stroke and
systemic embolism/clot formation in adult patients with non-
valvular AF with one or more of the following risk factors:
• Previous stroke, transient ischemic attack or systemic
embolism/clot formation.
• Left ventricular ejection fraction < 40%.
• Symptomatic heart failure > New York Heart Association
(NYHA) class 2.
• Age> 75 years.
• Age > 65 years in combination with additional vascular risk,
i.e., patients with diabetes mellitus, coronary artery disease or
arterial hypertension.
Published studies showed a 9% reduction in the prevention of
stroke or systemic embolism with dabigatran 110mg twice daily
and 34% for the 150mg twice daily (Malmström et al., 2013;
Marshall et al., 2013). Overall mortality was also reduced by 12%
for the highest dose of dabigatran, which reached statistical sig-
nificance (Mannuci et al., 2012; Malmström et al., 2013). There
was also an appreciable and consistent reduction in the risk of
haemorrhagic stroke ranging from 69 to 74% depending on the
dose of dabigatran. The 150mg twice daily dose of dabigatran also
resulted in a statistical significant reduction in ischemic stroke
(24% risk reduction) (Mannuci et al., 2012; Malmström et al.,
2013). Dabigatran could also potentially require no monitoring
compared with warfarin (Godman et al., 2012; Malmström et al.,
2013). As a result, dabigatran has the potential to be an important
new treatment, especially where regular monitoring with warfarin
is problematic or where there are adverse events or other patient
issues with warfarin.
These improvements, coupled with potential savings with
dabigatran with the opportunity to reduce patient monitor-
ing, resulted in incremental cost-effectiveness ratios (ICERs)
of GB£4831 (C5560)/Quality adjusted life year (QALY) in
patients under 80 vs. warfarin and GB£7090 (C8150) above 80
(Malmström et al., 2013). A similar study in Sweden estimated
the cost/QALY gained for dabigatran versus warfarin at C7742,
increasing to C12,449 in patients who were well controlled with
warfarin (Davidson et al., 2013). Other authors have published
higher ICERs, e.g., the National Institute for Health and Care
Excellence (NICE) increased the base case ICER for dabiga-
tran 150mg twice to GB£24,173–29,131 (C27,790–33,490)/QALY
with different assumptions (NICE, 2012). However, NICE sub-
sequently recommended dabigatran as an alternative to warfarin
in patients who meet the criteria outlined in the marketing
authorization approval (NICE, 2012).
However, there have been concerns with the rapid intro-
duction of dabigatran. There were an appreciable number of
serious adverse events within the first 12 weeks of dabiga-
tran’s availability in the US (Malmström et al., 2013). These
were principally serious bleeding events or blood clots in the
elderly (Malmström et al., 2013). Dabigatran was also the most
frequently identified medication involving direct safety-related
reports to the FDA in 2011. These include haemorrhage, which
was the most frequently reported side-effect (Carley et al., 2014).
These concerns arose due to dabigatran’s low mean oral bioavail-
ability, considerable variation in plasma drug concentrations,
and dependence on renal elimination of the active metabolite
KEY CONCEPT 2 | Dabigatran
The potential for inappropriate prescribing of dabigatran was a concern
among health authorities across countries given the considerable varia-
tion in plasma concentration levels among the target elderly population,
dependency on renal elimination of the active metabolite, no commer-
cially available assay at launch and no effective reversal agent at launch.
Consequently, the potential for serious bleeding and deaths if not admin-
istered appropriately, which happened in practice.
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(Mannuci et al., 2012;Malmström et al., 2013). Consequently, any
accumulation of dabigatran in patients with reduced renal func-
tion will increase their risk of excessive bleeding, complicated by
no effective reversal agent and no commercially available assay to
measure blood levels of dabigatran (Legrand et al., 2011; Harper
et al., 2012; Mannuci et al., 2012; Malmström et al., 2013; Xu
et al., 2013; Reilly et al., 2014). These concerns are enhanced by
potentially more elderly patients in clinical practice than seen in
the Phase III clinical studies with the belief this would increase
the risk of bleeding, which has now been demonstrated (Joppi
et al., 2013; Reilly et al., 2014). There were also concerns with
dabigantran’s budget impact (Malmström et al., 2013). A num-
ber of health authorities and health insurance companies across
Europe and other countries recognized these issues and initiated
extensive pre- and peri-launch programmes to educate physicians
and the public regarding the optimal use of dabigatran, especially
in elderly patients with poor renal function (Malmström et al.,
2013).
Consequently, we undertook a review of health authority and
health insurance company activities across Europe pre- to post-
launch of dabigatran for the prevention of stroke as an exemplar
for developing future models to better manage the entry of new
premium priced drugs. We subsequently used this knowledge
to suggest future activities that all key stakeholder groups could
undertake to optimize their use and reduce the likelihood of new
drugs being removed from the market place due to safety con-
cerns in a wider patient population. In addition, suggest activities
to help control expenditure on new drugs where there are con-
cerns with their budget impact. We have added to this advice
based on post-launch studies with dabigatran in a number of
countries.
METHODOLOGY
Principally a descriptive review of initial national, regional or
local health authority, health insurance company or physi-
cian association activities across Europe regarding dabigatran
(Malmström et al., 2013).
Demand-side initiatives were collated under four different
activities named the 4 Es—Education, Engineering, Economics
and Enforcement (Wettermark et al., 2009). Illustrations of
these include: (Wettermark et al., 2009; Godman et al., 2013;
Malmström et al., 2013):
• Educational activities—Ranging from simple distribution of
printed material to intensive strategies including academic
detailing and monitoring of prescribing habits against agreed
guidance usually by professional medical networks.
• Engineering activities—Organizational or managerial issues
to influence change, e.g., quality and efficiency prescribing
targets.
• Economic interventions—Financial incentives. These include
financial incentives for physicians if they achieve agreed pre-
scribing targets, devolution of drug budgets combined with
regular monitoring of prescribing behavior and fines for
prescribing costs above agreed limits as well as patient co-
payments.
• Enforcement—Regulations by law such as compulsory
International Non-proprietary Name (INN) prescribing, com-
pulsory generic substitution, or prescribing restrictions such
as restricting prescribing of new medicines to a defined patient
sub-population.
This has been supplemented by post launch studies evaluating
utilization patterns and patient populations in a range of coun-
tries and regions. These include Ireland, Italy, New Zealand,
Scotland, Slovenia, Spain (Catalonia) and Sweden (Stockholm
County Council). Typically, health authority databases and
patient registries were used to access relevant patient and utiliza-
tion data (Malmström et al., 2013).
RESULTS
HEALTH AUTHORITY AND HEALTH INSURANCE COMPANY ACTIVITIES
Table 1 summarizes some of the health authority and health
insurance company activities pre-, peri-, and post-launch up till
the end of 2012 (Malmström et al., 2013). Unless stated, the indi-
cations are those contained in the EMA marketing authorization
(Malmström et al., 2013).
PROPOSED MODEL AND ASSOCIATED ACTIVITIES
Figure 1 outlines the suggested new model to better manage the
utilization of newmedicines in the future. This is based on exten-
sive knowledge and experience including pre- to post-launch
activities with dabigatran shared across healthcare institutions.
This builds on the identified three pillars of pre, peri-, and
post-launch activities (Godman et al., 2012).
KEY CONCEPT 3 | Better manage the utilization of new medicines
Potential models can be developed to optimise the use of new medicines.
This starts pre-launch with horizon scanning, budgeting and physician edu-
cation, through peri-launch with critical evaluation of the potential role and
value of new medicines, and carrying onto post launch. Post launch activi-
ties include patient registries to monitor the prescribing of new medicines
including potential safety issues and outcomes, as well as the prescribing
against agreed guidance.
The proposed model starts with horizon scanning activi-
ties pre-launch. Post launch activities include monitoring cur-
rent prescribing, benchmarking and entering patient details on
registries.
Key issues for health authorities to consider when appraising
possible risk sharing arrangements or managed entry agreements
have already been summarized (Malmström et al., 2013). The
same applies to key issues and considerations before implement-
ing patient registries (Figure 1).
Overall, there are a number of activities that each key stake-
holder group should consider pre-, peri-, and post-launch to
better manage the entry of new drugs. This is especially important
where there are potential safety and/or resource issues with new
premium priced drugs (Malmström et al., 2013).
POST LAUNCH STUDIES
Italy
A recent study using a population-oriented database for medicine
use aimed to describe clinical features and pharmacological
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Table 1 | Summary of key activities across Europe to improve the quality and efficiency of prescribing of dabigatran (Malmström et al., 2013).
Timing Examples of activities among European countries and regions
Pre-launch (principally education) Stockholm County Council
• Systematic and long-term involvement of medical and scientific expertise in the development
of guidelines and advice to patients and prescribers through the Regional Drugs and
Therapeutic Committee (DTC) and clinical pharmacologists
• Extensive pre-launch activities with key messages broadcasted both to the public and to
prescribers through websites of the DTC as well as the Swedish Medical Journal
• Appreciable number of pre-launch meetings and training sessions with all major physician
groups around the key issues and concerns with dabigatran as well as its likely place in care
• Production of educational folders regarding dabigatran, slide kits, published articles, and data
on the Janus website as well as published information for patients
• Forecasting the potential budget impact in 2011 and 2012 ahead of launch and monitoring this
in practice
• Development of a laboratory method to monitor dabigatran in plasma with LC-MS/MS
technology, and recommending sampling in the introductory phase to build a knowledge
database. This to be followed by more situation-based sampling to improve patient safety in
the future
Peri-launch (principally education) (A) Germany
• Physician Associations stressing when launched that the current knowledge regarding safety
with dabigatran was insufficient to answer all questions, and physicians should be careful with
prescribing particularly in the elderly
• The reporting of deaths from excessive bleeding further endorsed these concerns. As a
result, limited prescribing in practice in ambulatory care
(B) Slovenia
• Reimbursed in conjunction with a complex price: volume agreement
Post-launch (principally education and enforcement) (A) Austria (education and enforcement)
• Publication of a guideline “Anticoagulants and Platelet Inhibitors” through a multi-stakeholder
initiative including health insurers (Arznei Vernunft, 2014)
• Ex ex-ante approval by the head physician of the patient’s social health insurance fund before
reimbursement of dabigatran; otherwise 100% co-payment (mirroring other situations)
• Renal function has to be assessed and recorded prior to initiation of therapy with dabigatran
through determining Creatinine-Clearance (CrCl) levels to exclude patients with severe renal
dysfunction (=CrCl <30ml/min). In addition during treatment, renal function has to be
monitored where a decline is envisaged, e.g., patients with hypovolaemia, dehydration and
the use of specific additional medication, and renal function has to be assessed at least once
a year in patients aged 75 or older, and/or in patients with compromized renal function
(B) Slovenia
• Education of all involved specialists and primary physicians on key safety aspects/ adverse
events with dabigatran
• Prescribing restrictions (Enforcement):
– Only reimbursed if initiated by an internist or neurologist and prescribed according to agreed
indications, e.g., only reimbursed in patients already on warfarin if they are unstable with
TTR < 65
– Patients have to be followed in a tertiary or secondary anticoagulation centre. Patients can
be followed in primary care but only if authorized by tertiary or secondary center
– Every patient has to be registered in a database and followed by the IT anticoagulation
programme
– Anticoagulation centers have to report once yearly to the tertiary center regarding the
number of patients experiencing minor and major bleeding, thromboembolic events, as
well as any deaths from bleeding or thromboembolism with dabigatran
– No longer a need to report separately to the National Health Insurance (ZZZS)
treatments of a population-based cohort of Italian patients
discharged from the hospital with a diagnosis of non-valvular
AF. Subsequently, to compare these patients with those included
in the RE-LY, ROCKET AF, and ARISTOTLE studies for dabi-
gatran, rivaroxaban, and apixaban respectively (Joppi et al.,
2013).
Of the 2,862,264 subjects considered for the study, 13,360
patients (0.47%) were discharged from hospitals with a diagnosis
of non-valvular AF. Their mean age was 76.3 (SD 10.7), 49.8%
were men and 64.6% were ≥75 years of age. This compares with
a mean age of 71.5 ± 8.7 in the Re-LY study, a proportion of
women< 40%, and approximately 40% ≥75 years of age.
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FIGURE 1 | Proposed model for optimizing the managed entry of new drugs across Europe incorporating national and regional stakeholder groups
where pertinent building on the example of dabigatran (Malmström et al., 2013).
Fifty percent of patients were treated with warfarin and
44.1% with antiplatelet agents. The proportion of patients on
antiplatelet therapy increased with age, up to a rate of 54.3%
in subjects ≥85 years. 92.9% of the studied cohort were on
polypharmacy (mean 8 drugs/patient). Approximately 20% of the
entire cohort was treated with amiodarone, a drug potentially
interfering with NOACs, and 3.6% from a subgroup analysis had
renal failure, which is an exclusion criterion in trials on NOACs
(Joppi et al., 2013).
The results of this survey demonstrate once more that con-
siderable efforts should be made by pharmaceutical compa-
nies and others to include more women and elderly people
in randomized clinical trials. Furthermore, while suggesting
a role for NOACs in satisfying patients’ needs, there is still
unmet need. Further phase IV studies are also required to con-
firm the benefits and clarify the safety profile of novel oral
anticoagulants in routine clinical practice (Malmström et al.,
2013).
New Zealand
A recent study conducted among patients recruited from the
medical services at Lower Hutt Hospital and two large general
practices in New Zealand also showed less predominance of men
than the RE-LY study (42 vs. 63%), an older cohort (73 vs. 71
years) and greater morbidity (Thorne et al., 2014). This is in keep-
ing with differences between patients seen in RCTs compared with
those in real life.
The authors did not observe inappropriate prescribing of dabi-
gatran according to patients’ renal function. They believed this
may reflect extensive local educational initiatives by the Best
Practice Advisory Centre (BPAC) as well as initiatives by local
prescribers pre- and peri-launch. This suggests that prescribers
can be educated to operate within accepted guidelines, provid-
ing guidance for the future (Thorne et al., 2014). There were
a high number of adverse events reported to New Zealand
Centre for Adverse Drug Reaction Monitoring after the launch
of dabigatran. However, increased publicity on adverse events
and increasing knowledge about dabigatran among prescribers
in New Zealand, especially regarding renal function, led to a
reduction in number of adverse reactions reported to the New
Zealand Centre for Adverse Drug Reaction Monitoring in recent
months (Thorne et al., 2014).
Ireland
Patterns of dabigatran prescribing were investigated in a national-
level prescription claims database. Dispensing records from
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January-October 2013 inclusive were studied and patients with
a dabigatran supply duration of greater than 35 days were
assumed to be non-valvular atrial fibrillation patients. 5887
(85%) patients were identified as having received dabigatran,
5012 (83%) of whom received the drug for >35 days. 62% of
patients who received dabigatran for >35 days were 75 years
or older and 37% were 80 years or older. 56% of patients were
male. A high proportion of patients were found to be con-
currently receiving drugs which may increase the bleeding risk
associated with dabigatran use: 36% of patients receiving dabi-
gatran for >35 days were found to have also received at least
one “caution” drug (defined as per SmPC) when dispensed
dabigatran.
This analysis followed publications from various author-
ities in Ireland as there were concerns with the prescrib-
ing of dabigatran in clinical practice (National Medicines
Information Centre, 2012; Barry, 2013; Irish Medicines Board,
2013). Following the analysis, a letter has now been sent
by the authorities to all physicians in Ireland reminding
them of the appropriate prescribing of NOACs based on the
findings.
Scotland
InMay 2008, the ScottishMedicines Consortium (SMC) accepted
dabigatran for use in the prevention of venous thromboem-
bolic events following total hip or total knee replacement
surgery (SMC, 2008). However, it was not until late 2011
with acceptance of its use by SMC for the prevention of
stroke and systemic embolism in adult patients with non-
valvular AF (SMC, 2011) that greater use was seen in ambu-
latory care (Figure 2) (Scott and McTaggart, 2013). Analysis of
the number of patients dispensed a prescription for dabiga-
tran showed a faster and much greater uptake in rural com-
pared with urban areas (Figure 2). The reasons for this are
currently being explored, but might reflect differences in access
to anticoagulant monitoring services and the perceived advan-
tage of dabigatran in this respect (Malmström et al., 2013).
The rates in Figure 2 were standardized against the population
aged 50 years or over to take account of different demograph-
ics and because this is the age group in which AF is most
common.
The overall use of dabigatran, as well as rivaroxaban, still
remains modest compared with warfarin in Scotland. This may
reflect extensive educational input pre- to post-launch high-
lighting where pertinent that warfarin should remain first line
treatment especially with no known antidote for dabigatran
(Malmström et al., 2013).
In contrast to the findings from the other countries described,
the population treated with dabigatran in Scotland appears much
closer in age and ratio ofmen to women to those patients included
in the RE-LY trial:
• Number of patients: 642 (M = 391, F = 251).
• Median age: 72 years (M = 69, F = 75 years).
• Mean age: 70.83 (M = 68.92 years, SD = 12.4; F = 73.81
years, SD = 11.599).
This may again reflect a greater use among a broader population
in rural areas; however, this remains to be proven. We acknowl-
edge though that we have not broken the ages of patients down by
indication. However as seen in Figure 2, there was limited use of
dabigatran in ambulatory care prior to SMC approval for its use
in patients with AF.
Slovenia
Recent analysis of the utilization of dabigatran and warfarin
by the Health Insurance Institute of reimbursed prescriptions
(Table 2) would suggest that the prescribing of dabigatran is being
restricted in accordance to the regulations (Table 1). However, the
FIGURE 2 | Patients per 100,000 population aged 50 years and over receiving a prescription for dabigatran by month and type of location (Scott and
McTaggart, 2013).
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Table 2 | Utilization of reimbursed anti-coagulants in Slovenia (DDDs/
One Thousand Inhabitants/Day – DID).
2009 2010 2011 2012 2013
Dabigatran 0.012 0.030 0.058 0.217 1.134
Warfarin 8.553 8.477 8.843 9.329 9.202
situation is being monitored in secondary and tertiary anticoagu-
lation centers.
There was some utilization of dabigatran prior to reimburse-
ment in August 2012. This may represent use in patients under-
going orthopaedic surgery.
Spain (Catalonia)
A number of activities were undertaken in Catalonia particu-
larly post launch to help optimize the prescribing of dabigatran
(Malmström et al., 2013). A recent follow-up of patients with
AF prescribed dabigatran in Catalonia showed the following
(Troncoso and Diogène, 2014):
• Patients were older than in the RE-LY study: median age: 77
vs. 71 years and proportion of men lower [52.4 vs. 64.3%]
and renal function was lower [creatinine clearance: 25.3% <
50mL/min vs. 19.4%].
• One-third of the patients followed up were >80 years old; of
the 631 patients, 103 were not receiving the recommended dose
of dabigatran.
• There were 298 (17.2%) patients with previous ischemic heart
disease and 36 (2.1%) patients with severe renal impairment
for whom dabigatran should be contraindicated.
• Renal function was not recorded in electronic records during
the previous year for 517 patients (30%), and a large number
of patients had been prescribed dosages of dabigatran that were
not recommended.
• Fifteen patients on dabigatran and oral verapamil were pre-
scribed dosages that are not recommended.
These findings suggest that additional activities are still needed in
Catalonia to improve the prescribing of dabigatran. These include
information to prescribers, electronic tools to support physicians’
decision-making as well as greater monitoring of the prescribing
of NOACs (Troncoso and Diogène, 2014).
Sweden (Stockholm County Council)
Analysis of 2363 patients receiving at least one prescription
for dabigatran in Stockholm County Council between 2012
and 2013 with a registered diagnosis of non-valvular AF five
years or less before the first prescription of dabigatran, and
excluding patients where the speciality code for patients’ first
prescription was surgery/orthopaedics, showed similar ages to
patients enrolled into the RE-LY study (Malmström et al., 2013)
(Table 3).
This compares with a recent analysis of 43,353 individuals
with non-valvular AF in the Stockholm County Council database
between 2006 and2010. The analysis showed 54% of patients were
Table 3 | Patient ages prescribed at least one prescription for
dabigatran 2012–2013.
n = Mean age Min age Max SD
(years) (years) (years)
Female 1002 (42.4%) 73.1 34 96 9.2
Male 1361 (57.6%) 68 24 95 10.7
Total 2363 70.2 24 96 10.4
NB, Age calculations were based on the patients’ age at the first prescription.
75 years or older, 39% were 80 years or older, and 44% of patients
were women (Forslund et al., 2013).
The strength of dabigatran prescribed varied by age, with lower
doses prescribed for more elderly patients:
• 66.9% dispensed 150mg with a mean age of 66.4.
• 30.1% dispensed 110mg with a mean age of 77.5 years.
• 3.0% dispensed 75mg with a mean age of 80.3 years.
Further analysis is planned to see if the lower doses prescribed in
patients with a mean ages of 77.5 and 80.3 years correlates with
poorer renal function through analyzing their electronic health
records.
Summary of the findings
The findings from these post launch studies demonstrate that
the patient population in clinical practice can be very different
to those enrolled in Phase III trials, making extraction from the
trial data sometimes difficult. They also demonstrate the need
for educating physicians pre-launch if there are safety concerns
and contra-indications with new products to reduce adverse drug
reactions post launch.
The studies also show the potential to pool the findings from
patient registries post launch to gain more rapid insights.
KEY CONCEPT 4 | Patient registries
Patient registries as well as the active monitoring of prescribing of dabi-
gatran were undertaken in a number of countries. These showed the age
of the patients in clinical practice was often higher than those seen in
the Phase III clinical trials and there was a higher proportion of women.
Pre- and peri-launch educational activities among health authorities helped
reduce potential adverse drug reactions; however, additional measures are
needed in some countries to address dosing concerns and contra-indications
to optimise the future prescribing of dabigatran.
DISCUSSION
Dabigatran and the other new oral anti-coagulants (NOACs) are
the result of a long search for an alternative to warfarin to prevent
strokes in patients with AF. However, the weighing of the advan-
tages and disadvantages associated with dabigatran, especially in
the elderly with poor renal function, needs to be judged carefully
and handled appropriately alongside the additional acquisition
costs of dabigatran (Malmström et al., 2013; Xu et al., 2013;
Carley et al., 2014). This was especially the case in this situation
with no widely available assay pre-launch, exacerbated by con-
cerns from the Company regarding the potential for undermining
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their message about no monitoring (Reilly et al., 2014; Thomas,
2014). These challenges resulted in an extensive range of activities
among health authorities, health insurance companies and physi-
cian associations across Europe pre- to post-launch to enhance its
appropriate use based on factors including age and kidney func-
tion (Malmström et al., 2013). Similar findings were seen in New
Zealand, Ontario, Canada and Wisconsin, USA (Xu et al., 2013;
Carley et al., 2014).
Cases of major bleeding and deaths that were seen with dabi-
gatran soon after its launch, justify the need for the suggested
model (Figure 1) to improve the managed entry of new drugs
(Legrand et al., 2011; Harper et al., 2012; Mannuci et al., 2012;
Malmström et al., 2013). The EMA also reported on 6 November
2011 that there had already been 256 spontaneous reports of seri-
ous bleeding resulting in deaths in the EudraVigilance database
(EMA, 2011).
Extensive activities among the authorities included edu-
cational activities pre-launch in Stockholm County Council,
Sweden, as well as post-launch activities among regions and local-
ities in Germany, Spain, Sweden, and the UK (Malmström et al.,
2013). There were also prescribing restrictions in some coun-
tries alongside the development of shared care protocols between
sectors. It is suggested these activities helped reduce subsequent
bleeding among patients in practice, especially among those with
poor renal function and, as a result, help preserve the availability
of dabigatran. However, it is difficult to substantiate this with-
out definite research. Having said this, some of the findings post
launch suggests that such activities helped enhance the appropri-
ate use of dabigatran (Carley et al., 2014; Thorne et al., 2014).
Further efforts are still needed in some countries to improve the
prescribing of dabigatran, e.g., Spain (Catalonia) (Troncoso and
Diogène, 2014).
There have also been issues with the additional costs of dabi-
gatran vs. warfarin at GB£919.80 (C1060) per patient per year
(UK) given the growing prevalence of AF with currently over
4.5 to 6 million patients across Europe and rising (Malmström
et al., 2013). However, there is less of a budget differential in
Sweden (Davidson et al., 2013). These combined issues led to
(i) prescribing restrictions in some countries alongside prior
authorization schemes, e.g., Austria, Belgium, Finland, Slovakia,
and Slovenia, (ii) delays with reimbursement in others including
Croatia (recently reimbursed as second line to warfarin with a
50% co-payment), the Netherlands, Norway and Portugal (150
mg); and (iii) price: volume and other agreements (risk sharing)
to lower the cost of dabigatran, e.g., Ireland, the Netherlands and
Slovenia [2]. These concerns also resulted in dabigatran not being
reimbursed in some countries, e.g., Estonia, Lithuania, Poland,
the Republic of Serbia and the Republic of Srpska (constitutive
entity in Bosnia and Herzegovina). Prescribing restrictions and
risk sharing arrangements are no doubt preferred by manufactur-
ers versus not having their drugs reimbursed.
The weighing of the benefits and concerns with dabiga-
tran make it increasingly important for European countries and
regions to develop and refine models to further improve the
managed entry of new premium priced drugs, even if they do
not have a tradition of Health Technology Assessment (HTA).
As mentioned, the alternative could be reduced resources to
fund new drugs in the future, especially with a growing elderly
population, which is already happening (Malmström et al., 2013).
Such models may also reduce the possibility of new drugs such
as dabigatran being withdrawn from the market due to a greater
level of side-effects in a wider co-morbid population. None of
these alternative scenarios are in the best interests of any key
stakeholder group.
We hope we have demonstrated why it is imperative that health
authorities and health insurance agencies continue to develop and
refine new models to better manage the entry of new drugs. We
hope we have also provided direction to all key stakeholder groups
to further stimulate the debate about potential activities in this
critically important area. This especially as the constant introduc-
tion of new premium priced drugs is seen as the greatest chal-
lenge to the continued provision of equitable and comprehensive
healthcare in Europe (Garattini et al., 2008).
CONCLUSION
There were multiple activities pre- to post-launch among
authorities across Europe and other countries to improve the
prescribing of dabigatran, especially in elderly patients where
there are concerns with their renal function. In addition,
address potential concerns with the budget impact of dabigatran
through for instance price: volume agreements and prescribing
restrictions.
We believe and recommend, based on the experiences with
dabigatran and other new premium priced drugs, that it is essen-
tial that health authorities develop new models to better manage
the entry of new drugs in the future (Figure 1). This is becoming
critical given the considerable number of new biological drugs in
development (Evaluate Pharma, 2012).
Critical activities for health authorities pre-launch include
horizon scanning and budget planning activities. This includes
identifying products likely to lose their patent within the next
one to two years. This is because the price of generics can be as
low as 2–10% of pre-patent loss prices, with activities to enhance
the prescribing of low cost generics realizing considerable savings
(Godman et al., 2013).
Educational materials and clinical guidance also need to be
developed pre-launch with the help of physicians and patient
groups. Key peri-launch activities include developing prescribing
indicators for new treatments as well as the critical appraisal of
any proposed risk sharing arrangements. Increasingly discounts
are preferred for new drugs rather than complicated arrange-
ments including outcome schemes in view of the complexities
involved (Adamski et al., 2010; Ferrario and Kanavos, 2013).
Essential post launch activities include monitoring of prescribing
against agreed guidance with further educational input if needed.
Activities also include increasingly entering patients into registries
to monitor the effectiveness and safety of new drugs in wider
patient populations.
Without such models, authorities may well struggle to main-
tain the European ideals of equitable and comprehensive health-
care as well as ensuring funding for new “valued” treatments in
target populations. Consequently, the development of new mod-
els to better manage the entry of new drugs should be in the
interest of all key stakeholder groups.
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